Cancer has become the leading cause of death. The progress in diagnosis and treatment is still limited. Over the past three decades, emergence and rapid development of nanotechnology have brought new hopes for cancer therapy.
A repertoire of nanomaterials with controllable size-, shape-, and composition-dependent physiochemical properties has been studied for drug delivery and biomarker detection. Microfluidic devices have been designed for circulating tumor cell isolation and sensitive diagnosis of biomarker panels. To date, more than 247 nanomaterials-based products have been approved by the Food and Drug Administration (FDA) in USA for clinical application 1 at the University of California, Santa Barbara, used goldcoated silica nanoparticles for photothermal treatment of acne using low-frequency ultrasound as an enhanced delivery tool. The exciting achievements from clinical transformation of nanomaterials provided vast commercial opportunities. To accelerate the translation process, the following points should be addressed 6 : (I) a thorough understanding of the nanostructures and interaction between rational design of nanomaterials and physiological microenvironment; (II) molecular probes and engineered nanoprobes for preclinical and activatable prognosis treatment; (III) stimuli-responsive smart drug delivery systems for targeted therapy, especially clinical EPR effects; (IV) imaging guided therapy and surgery with theranostic nanoparticles; (V) safety considering, especially nanotoxicity in vivo; (VI) multidisciplinary integration and multi-disciplinary team (MDT) cooperation for translational nanomedicine. Cancer stem cells (CSCs) play a critical role in the tumor occurrence, deterioration, metastasis, and recurrence 7 . Specific targeting and removal of CSCs may be essential for the effective treatment and prevention of cancer. Nanomaterials as drug delivery system or imaging probe have been successfully applied for highly sensitive imaging and efficient therapy of CSCs 8 .
Moreover, tumor microenvironment also allows for growth and metastasis of tumor cells, and aids in the resistance of cancer cells to current chemotherapy and radiotherapy 9 . Currently developed nanoprobe could selective bind with cancer cells and exhibit a high imaging sensitivity 10 . Therefore, nanotechnology is prone to design and synthesis of nanomedicine or nanoprobe for treatment of CSCs and tumor microenvironment.
By and large, with the quick development of nanotechnology, we need to advocate for a large scale multidisciplinary effort aiming at clinical transformation. We encourage more scientists to join in this exciting and prospective field.
